Efficacy of Faviprevir in COVID-19 Treatment

Tanta University

Status and phase: Completed; Phase 3; Phase 2

Conditions: COVID

Treatments: Drug: Favipiravir; Drug: Chloroquine

Study type: Interventional

Funder types: Other

Identifiers

NCT04351295

faviprevir covid

Details and patient eligibility

About

Faviprevir in COVID-19 treatment

Full description

Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 treatment

Enrollment: 92 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with covid 19

Exclusion criteria

• Allergy or contraindications to faviprevir

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

92 participants in 2 patient groups

Faviprevir

Experimental group

Description:

Faviprevir

Treatment:

Drug: Favipiravir

chloroquine

Active Comparator group

Description:

chloroquine

Treatment:

Drug: Chloroquine